Suppr超能文献

前列腺癌风险评估(CAPRA)术前评分与术后评分(CAPRA-S):预测癌症进展的能力及根治性前列腺切除术后辅助治疗的决策制定。

Cancer of the Prostate Risk Assessment (CAPRA) Preoperative Score Versus Postoperative Score (CAPRA-S): ability to predict cancer progression and decision-making regarding adjuvant therapy after radical prostatectomy.

作者信息

Seo Won Ik, Kang Pil Moon, Kang Dong Il, Yoon Jang Ho, Kim Wansuk, Chung Jae Il

机构信息

Department of Urology, Busan Paik Hospital, Inje University, Busan, Korea.

出版信息

J Korean Med Sci. 2014 Sep;29(9):1212-6. doi: 10.3346/jkms.2014.29.9.1212. Epub 2014 Sep 2.

Abstract

The University of California, San Francisco, announced in 2011 Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) score which included pathologic data, but there were no results for comparing preoperative predictors with the CAPRA-S score. We evaluated the validation of the CAPRA-S score in our institution and compare the result with the preoperative progression predictor, CAPRA score. Data of 130 patients were reviewed who underwent radical prostatectomy for localized prostate cancer from 2008 to 2013. Performance of CAPRA-S score in predicting progression free probabilities was assessed through Kaplan Meier analysis and Cox proportional hazards regression test. Additionally, prediction probability was compared with preoperative CAPRA score by logistic regression analysis. Comparing CAPRA score, the CAPRA-S score showed improved prediction ability for 5 yr progression free survival (concordance index 0.80, P = 0.04). After risk group stratification, 3 group model of CAPRA-S was superior than 3 group model of CAPRA for 3-yr progression free survival and 5-yr progression free survival (concordance index 0.74 vs. 0.70, 0.77 vs. 0.71, P < 0.001). Finally the CAPRA-S score was the more ideal predictor concerned with adjuvant therapy than the CAPRA score through decision curve analysis. The CPARA-S score is a useful predictor for disease progression after radical prostatectomy.

摘要

加利福尼亚大学旧金山分校于2011年公布了前列腺癌术后风险评估(CAPRA-S)评分,该评分纳入了病理数据,但尚无将术前预测指标与CAPRA-S评分进行比较的结果。我们评估了CAPRA-S评分在本机构中的有效性,并将结果与术前进展预测指标CAPRA评分进行比较。回顾了2008年至2013年期间130例行局限性前列腺癌根治性前列腺切除术患者的数据。通过Kaplan Meier分析和Cox比例风险回归测试评估CAPRA-S评分预测无进展概率的性能。此外,通过逻辑回归分析将预测概率与术前CAPRA评分进行比较。与CAPRA评分相比,CAPRA-S评分在预测5年无进展生存率方面显示出更高的预测能力(一致性指数0.80,P = 0.04)。在进行风险组分层后,CAPRA-S的3组模型在3年无进展生存率和5年无进展生存率方面优于CAPRA的3组模型(一致性指数分别为0.74对0.70、0.77对0.71,P < 0.001)。最后,通过决策曲线分析,CAPRA-S评分比CAPRA评分更适合作为辅助治疗的预测指标。CAPRA-S评分是根治性前列腺切除术后疾病进展的有效预测指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af6e/4168173/449fc262d62a/jkms-29-1212-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验